How to Use AI for a Neurology Practice in 2026: AAN Guidelines, Stroke + Epilepsy + MS + Headache, MIPS, HIPAA, and the Owner Scorecard
Published June 10, 2026 · 14 min read
The 7-Layer AI Stack for Modern Neurology Practices
| Layer | Purpose | Tools |
|---|---|---|
| Intake | Pre-visit + headache + seizure diary intake | Phreesia + NexHealth + Klara + Notable + Solv + Luma Health |
| Ambient SOAP | SOAP + E/M leveling + orders | DAX Copilot + DeepScribe + Abridge + Suki + Heidi + Freed + Augmedix + Sunoh.ai |
| EHR + PM | Charts + orders + billing + imaging | Epic + Cerner + athenahealth + eClinicalWorks + Greenway + Modernizing + NextGen |
| Decision Support | Stroke + EEG + MS + cognitive AI | RAPID + Viz.ai + Aidoc + Heuro + Persyst + Aural Analytics + Encevis + icometrix + QyScore |
| Prior-Auth | DMT + biologic + AED + DBS + IT pump appeal | CoverMyMeds + Glidian + Surescripts + Cohere + Banjo + Myndshft + AssistRx |
| Compliance | HIPAA + AKS + AI-scribe consent | Drata + Vanta + Compliancy + MedTrainer + HIPAA One + Keragon + SAFER |
| Outreach | Recall + reviews + survivorship | Weave + Solutionreach + Demandforce + Podium + BirdEye + NiceJob + Phreesia |
10 Copy-Paste Prompts for Neurology Practices
- AI pre-visit intake + headache + seizure + MS relapse diary — Triage inbound for visit type (new + follow-up + post-stroke + post-seizure + DMT infusion + DBS programming + cognitive eval), HPI scaffold, headache calendar (frequency + duration + intensity + aura + triggers + abortive use), seizure semiology + AED + drug-level, MS relapse + EDSS + ARR, meds reconciliation + DDI flags, family hx (PD + AD + ALS + epilepsy), and ICD-10 tee-up.
- Ambient neurology SOAP — Generate SOAP with subjective + objective (cranial nerves + motor + sensory + reflexes + coordination + gait + MoCA/MMSE + EDSS + UPDRS + ALSFRS-R + NIHSS), assessment (ICD-10 I63 + G40 + G35 + G43 + G44 + G20 + G30 + G12), plan (DMT + AED + CGRP biologic + symptom care + imaging + EEG + LP + neuropsych + DME), CPT 99202-99215 + 95812-95830 EEG + 95860-95887 EMG/NCS + 96116-96133 cognitive testing. Neurologist review required.
- Stroke triage + LVO detection workflow — Integrate NIHSS + LKW + ASPECTS + LVO detection (RAPID + Viz.ai + Aidoc) + perfusion mismatch (DEFUSE-3 + DAWN) per AHA/ASA 2019 + 2024 update. Output IV alteplase + tenecteplase + thrombectomy decision; flag contraindications; auto-draft door-to-needle + door-to-puncture timeline.
- Epilepsy AED + drug-level + EEG pathway — From seizure type per ILAE 2017 operational + 2025 update classification, generate AED options (Briviact + Xcopri + Fycompa + lacosamide + perampanel + valproate + levetiracetam + lamotrigine + topiramate), drug-level monitoring, AED-AED + AED-DOAC DDI, EEG auto-detection via Persyst + Aural Analytics + Encevis. Cite AAN + AES guidelines.
- MS DMT selection pathway — Apply AAN + ECTRIMS + MAGNIMS MRI criteria + JCV serology + lymphocyte count to DMT selection (ocrelizumab + ofatumumab + ublituximab + cladribine + S1P modulators + dimethyl + diroximel + monomethyl fumarate + teriflunomide + glatiramer + interferon-beta). Output relapse-rate + EDSS + MRI activity goals + lab monitoring schedule.
- Headache + migraine biologic pathway — Apply IHS-3 classification + AHS Choosing Wisely; output anti-CGRP biologic (erenumab + fremanezumab + galcanezumab + eptinezumab) + ditans (lasmiditan) + gepants (ubrogepant + rimegepant + atogepant + zavegepant) + onabotulinumtoxinA chronic migraine eligibility per insurer step-therapy + state step-therapy reform 30+ states.
- Parkinson + DBS + advanced therapy pathway — From UPDRS + LEDD + motor fluctuations + dyskinesia, output DBS candidacy, Vyalev (foslevodopa + foscarbidopa SC infusion) eligibility, Inbrija + Gocovri + Nourianz add-on, Apokyn rescue. Cite MDS + AAN guidelines.
- Cognitive impairment + AD biomarker pathway — From MoCA + MMSE + neuropsych + AD biomarker blood test (FDA-approved 2025) + amyloid PET + CSF tau/Abeta42 ratio, output lecanemab + donanemab eligibility (early symptomatic AD + amyloid-positive + ApoE4 status + MRI for ARIA risk) per AAN + Alzheimer's Association Appropriate Use Criteria 2024+2025.
- State AI-scribe consent + HIPAA gating — For each new patient, surface state AI-scribe consent (CA AB 3030 + TX SB 815 + UT HB 452 + IL HB 1806) + FSMB Model Policy on AI 2024. Confirm BAA + minimum-necessary + access logs. Block ambient until consent captured.
- Owner monthly scorecard — Track visits/MD-day, EEG + EMG/NCS room utilization, MIPS MVP Optimal Care for Patients with Episodic Neurological Conditions scores, DMT infusion-suite utilization, stroke door-to-needle + door-to-puncture, prior-auth turnaround + denial rate, AKS/Stark/Sunshine $13.46/$134.49 FY 2026 spend audit, OIG LEIE + GSA SAM.gov screen.
The 12-Item Neurology Compliance Floor
- HIPAA Privacy + Security + Breach Notification 45 CFR 160 + 164 + BAA with every AI vendor
- State medical-board scope + AI-scribe consent (CA AB 3030 + TX SB 815 + UT HB 452 + IL HB 1806)
- AAN + AHA/ASA + ECTRIMS + ILAE + AES + IHS-3 + AHS + MDS guideline alignment
- CMS E/M 2021+2023 + AMA CPT 2026 + ICD-10-CM Oct 1 2025 + EEG + EMG/NCS coding
- MIPS MVP Optimal Care for Patients with Episodic Neurological Conditions attestation accuracy
- FDA REMS for clozapine + Mavyret + cladribine + lecanemab + donanemab + state-specific REMS audits
- State step-therapy reform 30+ states for DMT + anti-CGRP + AED appeal
- FDA 510(k) + De Novo AI-SaMD list (RAPID + Viz.ai + Aidoc + Persyst + icometrix)
- AKS 42 USC §1320a-7b + Stark §1395nn + Sunshine $13.46/$134.49 FY 2026 spend log
- FTC Endorsement Guides 2023 + Fake Reviews Rule 16 CFR 465 $51,744/violation FY 2026
- TCPA 47 USC §227 + state mini-TCPA + FCC 2024 one-to-one + quiet hours 8am-9pm
- OIG LEIE + GSA SAM.gov exclusion screen + state Medicaid exclusion list (monthly)
60-Day Rollout Plan
Days 1-15: HIPAA + state AI-scribe consent audit; ambient SOAP pilot with one MD; stroke triage AI baseline; MIPS MVP measure baseline.
Days 16-30: Roll ambient SOAP to all MDs; epilepsy AED + EEG dashboard live; MS DMT pathway live; prior-auth queue (ocrelizumab + ofatumumab + cladribine + anti-CGRP + Briviact + Xcopri + Fycompa + Inbrija + Vyalev + lecanemab + donanemab).
Days 31-45: MIPS MVP gap-close sprint; PD + DBS pathway live; AD biomarker + lecanemab + donanemab pipeline; RPM smart-watch seizure detection live.
Days 46-60: Owner scorecard live; AKS/Sunshine spend audit; FTC + TCPA refresh; OIG LEIE monthly screen; ACO + value-based contract reconciliation.
8 Mistakes That Kill Neurology AI Rollouts
- Auto-finalizing ambient SOAP without neurologist review (DMT + AED + ICD-10 errors)
- Treating LVO detection AI as ground truth without human read confirmation
- Skipping JCV serology + lymphocyte count + MRI for DMT selection
- Inventing MIPS MVP attestations (CMS audit + clawback)
- Skipping state AI-scribe consent (CA AB 3030 + TX SB 815 + UT HB 452 + IL HB 1806)
- Submitting lecanemab + donanemab prior-auth without ApoE4 + MRI ARIA monitoring plan
- Ignoring AKS/Stark on AI vendor fee-splitting or referral-volume kickbacks
- Treating vendor AI dashboards as truth without validating against EHR + claims
Frequently Asked Questions
What is the single biggest 2026 AI risk for a neurology practice?
Two tied: (1) Stroke triage errors — AI tools that auto-suggest tPA + tenecteplase + thrombectomy without integrating NIHSS + onset time + LVO criteria + ASPECTS + perfusion mismatch (RAPID + Viz.ai + Aidoc) per AHA/ASA 2019 + 2024 update + DEFUSE-3 + DAWN extended window create medico-legal exposure when LKW windows or contraindications are missed. (2) Disease-modifying therapy errors — AI clinical-decision tools that don't reconcile against current AAN + ECTRIMS MS guidelines, ILAE + AES epilepsy classification (operational 2017 + ILAE 2025 update), AHS + IHS-3 headache classification, and prior-auth criteria for ocrelizumab + ofatumumab + ublituximab + cladribine + ofatumumab + S1P modulators + anti-CGRP migraine biologics + Wakix/Sunosi/Xywav + Briviact + Xcopri + Fycompa trigger inappropriate switches + denied PA + Medicare audit.
Can ambient AI scribes document neurology SOAP notes correctly?
Yes — DAX Copilot, DeepScribe, Abridge, Suki, Heidi, Freed, Sunoh.ai, Augmedix support ambient neurology SOAP with subjective (HPI + headache pattern + seizure semiology + MS relapse + cognitive timeline + sleep + functional status), objective (vitals + cranial nerves + motor + sensory + reflexes + coordination + gait + cognitive screen MoCA/MMSE + EDSS + UPDRS + ALSFRS-R), assessment (ICD-10 G00-G99 + I63 stroke + G40 epilepsy + G35 MS + G43-G44 migraine + G20 PD + G30 AD + G12 ALS), plan (DMT + AED + CGRP biologic + symptom care + imaging + EEG + LP + neuropsych referral + DME), and CPT 99202-99215 + 95812-95830 EEG + 95860-95887 EMG/NCS + 95940 IOM + 95937 NMJ + 96116/96121/96132/96133 cognitive testing. Output requires neurologist review; never auto-finalize.
How does AI fit MIPS MVP reporting for neurology?
CMS finalized MIPS MVP Optimal Care for Patients with Episodic Neurological Conditions for 2025 with continued refinement for 2026. Quality measures applicable include Q009 anti-thrombotic at discharge for stroke + TIA, Q032 stroke therapy LDL management, Q187 carotid imaging for ischemic stroke, Q419 documentation of meds, Q047 advance-care plan, Q418 osteoporosis screening for women on AED, Q226 tobacco screening + cessation, Q134 depression screening, Q130 documentation of meds, Q110/Q111 immunization. AI helps via gap-list automation, pre-visit reconciliation, post-visit gap-close, and clean attestation accuracy. Documentation must match measure spec; never let AI invent attestations.
What neurology workflows benefit most from AI?
Stroke triage (NIHSS scoring + LVO detection + ASPECTS + perfusion mismatch via RAPID + Viz.ai + Aidoc + Heuro for IV thrombolysis + thrombectomy decision per AHA/ASA 2019 + 2024 update + DEFUSE-3 + DAWN); epilepsy management (AED selection + drug-level + ILAE 2017 operational + 2025 update classification + EEG auto-detection via Persyst + Aural Analytics + Encevis); MS DMT pathway (AAN + ECTRIMS + MAGNIMS MRI + JCV serology + lymphocyte count + S1P + B-cell depletion + cladribine + ofatumumab + ublituximab eligibility); headache pathway (IHS-3 + AHS Choosing Wisely + anti-CGRP biologic + ditans + gepants + onabotulinumtoxinA chronic migraine prior-auth); Parkinson + DBS pathway (UPDRS + LEDD + DBS candidacy + Inbrija + Gocovri + Nourianz + Vyalev); ALS care (ALSFRS-R + edaravone + tofersen + Relyvrio); cognitive + dementia workup (MoCA + MMSE + neuropsych + AD biomarker FDA-approved blood test + lecanemab + donanemab anti-amyloid eligibility); RPM EEG + smart-watch seizure detection.
What is realistic ROI in 90 days?
Conservative targets: ambient SOAP rollout → 60-90 minutes/day saved per MD + 15-25 percent more visit slots; AI stroke triage + LVO detection → 15-30 minute door-to-needle + door-to-puncture reduction (per AHA/ASA target metric); AI prior-auth + denial appeal (ocrelizumab + ofatumumab + cladribine + anti-CGRP + Briviact + Xcopri + Fycompa + Inbrija + Vyalev + lecanemab + donanemab) → 20-30 percent denial-rate reduction; AI MIPS gap closure → 8-15 percentage-point lift on quality measures; AI patient messaging triage → 35-50 percent inbox-time reduction; RPM smart-watch seizure detection + EEG home monitoring → 2-4x increase in seizure capture for refractory epilepsy. Validate against EHR + claims + MIPS dashboards, not vendor self-reports.
Authoritative Sources
- AAN Clinical Practice Guidelines + Continuum + Neurology + Neurology Clinical Practice
- AHA/ASA Guidelines for Stroke 2019 + 2024 update + DEFUSE-3 + DAWN
- ECTRIMS + MAGNIMS MS guidelines + ILAE + AES epilepsy classification + IHS-3 + AHS headache
- CMS E/M 2021+2023 office-visit guidelines + MIPS MVP Optimal Care for Patients with Episodic Neurological Conditions 2026
- HIPAA Privacy + Security + Breach Notification 45 CFR 160 + 164
- State AI-scribe statutes (CA AB 3030 + TX SB 815 + UT HB 452 + IL HB 1806)
- FSMB Model Policy on AI 2024 + FDA 510(k) + De Novo AI-SaMD list + REMS programs + AKS + Stark + Sunshine + AMA CPT 2026 + ICD-10-CM Oct 1 2025